首页> 外文期刊>Trends in pharmacological sciences >Pharmacological Modulation of Transcriptional Coregulators in Cancer
【24h】

Pharmacological Modulation of Transcriptional Coregulators in Cancer

机译:癌症转录核心试剂的药理调节

获取原文
获取原文并翻译 | 示例
           

摘要

Upon binding of transcription factors to cis-regulatory DNA sequences, transcriptional coregulators are required for the activation or suppression of chromatin-dependent transcriptional signaling. These coregulators are frequently implicated in oncogenesis via causal roles in dysregulated, malignant transcriptional control and represent one of the fastest-growing target classes in small-molecule drug discovery. However, challenges in targeting coregulators include identifying evidence of cancer-specific genetic dependency, matching the pharmacologically addressable protein fold to a functional role in disease pathology, and achieving the necessary selectivity to exploit a given genetic dependency. We discuss here how recent trends in cancer pharmacology have confronted these challenges, positioning coregulators as tractable targets in the development of new cancer therapies.
机译:转录因子与顺式调节DNA序列的结合后,转录核心试剂需要激活或抑制染色质依赖性转录信号传导。 这些Coregulators经常通过具有多疑,恶性转录对照中的因果作用而涉及的血管生成,并且代表小分子药物发现中生长增长最快的靶等级之一。 然而,靶向核心特征中的挑战包括鉴定癌症特异性遗传依赖性的证据,将药理学上可寻性的蛋白质折叠与疾病病理学中的功能作用相匹配,并实现了利用给定的遗传依赖性的必要选择性。 我们讨论了近期癌症药理学的趋势如何面临这些挑战,将核心调节器定位为新癌症疗法的贸易目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号